

SIgN affiliated publications by Cheng-I WANG

Last updated: 29 May 2025

2024

Murali TM, Gu Y, Minhat RA, Yap J, Wood KJ, [Wang CI](#), Gascoigne NRJ, Anantharaman V, MacAry PA. Antigen-antibody complex density and antibody-induced HLA protein unfolding influence Fc-mediated antibody effector function. *Front Immunol*. 2024 Dec 18;15:1438285.

Goh YS, Fong SW, Hor PX, Loh CY, Tay MZ, [Wang B](#), [Salleh SNM](#), [Ngoh EZX](#), Lee RTC, Poh XY, Lee IR, Rao S, Chia PY; PRIBIVAC Cohort Study Group; Maurer-Stroh S, [Wang CI](#), Leo YS, Lye DC, Young BE, Ng LFP, Renia L. Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1). *Int J Infect Dis*. 2024 Jun 28;146:107147.

Salem GM, Galula JU, Wu SR, Liu JH, Chen YH, Wang WH, Wang SF, Song CS, Chen FC, Abarientos AB, Chen GW, [Wang CY](#), Chao DY. Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus. *Commun Biol*. 2024 Jan 24;7(1):15.

2023

Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L; NCID Study Group; COVID-19 Cohort Study Group. Variant-specific IgA protects against Omicron infection. *J Infect Dis*. 2023 Nov 23;jiad525.

Goh YS, Fong SW, Tay MZ, Rouers A, Chang ZW, Chavatte JM, Hor PX, Loh CY, Huang Y, Tan YJ, Wang B, Ngoh EZX, Mohd Salleh SN, Lee RTC, Lim G; NCID Study Group; COVID-Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lin RTP, Lam MC, Lye DC, Young BE, Ng LFP, Renia L. Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave. *Sci Rep*. 2023 Nov 7;13(1):19331.

Tulsian NK, Palur RV, Qian X, Gu Y, D/O Shunmuganathan B, Samsudin F, Wong YH, Lin J, Purushotorman K, Kozma MM, Wang B, Lescar J, Wang CI, Gupta RK, Bond PJ, MacAry PA. Defining neutralization and allostery by antibodies against COVID-19 variants. *Nat Commun*. 2023 Nov 1;14(1):6967.

Chang ZW, Goh YS, Rouers A, Fong SW, Tay MZ, Chavatte JM, Hor PX, Loh CY, Huang Y, Tan YJ, Neo V, Kam IKJ, Yeo NK, Tan EX, Huang D, Wang B, Salleh SNM, Ngoh EZX, Wang CI, Leo YS, Lin RTP, Lye DCB, Young BE, Muthiah M, Ng LFP, Rénia L; COVID-19 Study Group. Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB. *Front Immunol*. 2023 Jul 3;14:1206016.

Siddiqui AA, Peter S, Ngoh EZX, Wang CI, Ng S, Dangerfield JA, Gunzburg WH, Dröge P, Makhija H. A versatile genomic transgenesis platform with enhanced λ integrase for human Expi293F cells. *Front Bioeng Biotechnol*. 2023 Jun 22;11:1198465.

Lim PY, Ramaprabha A, Loy T, Rouers A, Thein TL, Leo YS, Burton DR, Fink K, Wang CI. A nonstructural protein 1 capture enzyme-linked immunosorbent assay specific for dengue viruses. *PLoS One*. 2023 May 18;18(5):e0285878.

Sampei Z, Koo CX, Teo FJ, Toh YX, Fukuzawa T, Gan SW, Nambu T, Ho A, Honda K, Igawa T, Ahmed F, Wang CI, Fink K, Nezu J. Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement. *Antibodies (Basel)*. 2023 May 15;12(2):36.

Tay MZ, Goh YS, Fong SW, Chang ZW, Rouers A, Wong N, Torres-Ruesta A, Huang Y, Selvam SK, Hor PX, Loh CY, Wang B, Mohd Salleh SN, Ngho EZX, Lee RTC, Neo V, Kam IKJ, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J; NCID Study Group; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lin RTP, Lye DC, Young BE, Ng LFP, Renia L. Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant. *Lancet Reg Health West Pac*. 2023 Apr;33:100732.

2022

Goh YS, Rouers A, Fong SW, Zhuo NZ, Hor PX, Loh CY, Huang Y, Neo VK, Kam IKJ, Wang B, Ngho EZX, Salleh SNM, Lee RTC, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES; NCID Study Group; COVID-19 Study Group, Maurer-Stroh S, Wang CI, Leo YS, Ren EC, Lye DC, Young BE, Ng LFP, Renia L. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. *Front Immunol*. 2022 Nov 14;13:1031852.

Rouers A, Wong N, Goh YS, Torres-Ruesta A, Tay MZ, Chang ZW, Fong SW, Neo V, Kam IKJ, Yeo NK, Huang Y, Loh CY, Hor PX, Wong JXE, Tan YJ; COVID-19 Study Group, Macary PA, Qian X, Bei W, Ngho EZX, Salleh SNM, Wang CI, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Lim C, Teo J, Ren EC, Lye DC, Young BE, Ng LFP, Renia L. Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters. *J Med Virol*. 2022 Oct 27:e28258.

Goh YS, Fong SW, Rouers A, Chang ZW, Tay MZ, Chavatte JM, Zhuo NZ, Hor PX, Loh CY, Huang Y, Wong JXE, Tan YJ, Lim DRX, Wang B, Ngho EZX, Salleh SNM, Lee RTC, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES; NCID Study Group; COVID-19 Study Group, Maurer-Stroh S, Wang CI, Leo YS, Lin RT, Ren EC, Lye DC, Young BE, Lim PL, Ng LF, Renia L. Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. *Clin Transl Immunology*. 2022 Aug 23;11(8):e1403.

Renia L, Goh YS, Rouers A, Le Bert N, Chia WN, Chavatte JM, Fong SW, Chang ZW, Zhuo NZ, Tay MZ, Chan YH, Tan CW, Yeo NK, Amrun SN, Huang Y, Wong JXE, Hor PX, Loh CY, Wang B, Ngho EZX, Salleh SNM, Carissimo G, Dowla S, Lim AJ, Zhang J, Lim JME, Wang CI, Ding Y, Pada S, Sun LJ, Somani J, Lee ES, Ong DLS; SCOPE Cohort Study Group, Leo YS, MacAry PA, Lin RTP, Wang LF, Ren EC, Lye DC, Bertoletti A, Young BE, Ng LFP. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. *Nat Commun*. 2022 Aug 8;13(1):4615.

Lin WN, Tay MZ, Wong JXE, Lee CY, Fong SW, Wang CI, Ng LFP, Renia L, Chen CH, Cheow LF. Rapid microfluidic platform for screening and enrichment of cells secreting virus neutralizing antibodies. *Lab Chip*. 2022 Jun 13. [Epub ahead of print]

Prasad M, Ponnalagu S, Zeng Q, Luu K, Lang SM, Wong HY, Cheng MS, Wu M, Mallilankaraman K, Sobota RM, Lim YT, Wang LC, Goh CK, Tay KXJ, Loh KS, Wang CI, Lee WH, Goh BC, Lim CM, Schwarz H. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape

immune surveillance and enables targeting by chimeric antigen receptors. *Cancer Immunol Immunother*. 2022 Mar 17. [Epub ahead of print]

Tay MZ, Rouers A, Fong SW, Goh YS, Chan YH, Chang ZW, Xu W, Tan CW, Chia WN, Torres-Ruesta A, Amrun SN, Huang Y, Hor PX, Loh CY, Yeo NK, Wang B, Ngoh EZX, Salleh SNM, Chavatte JM, Lim AJ, Maurer-Stroh S, Wang LF, Lin RT, Wang CI, Tan SY, Young BE, Leo YS, Lye DC, Renia L, Ng LFP. Decreased memory B cells frequencies in COVID-19 Delta variant vaccine breakthrough infection. *EMBO Mol Med*. 2022 Jan 6:e15227.

Kuramochi T, Gan SW, Ho AWS, Wang B, Kageji N, Nambu T, Iida S, Okuda-Miura M, Chia WS, Yeo CY, Chen D, Lee WH, Ngoh EZX, Mohd Salleh SN, Wang CI, Igawa T, Shimada H. Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants. *MAbs*. 2022 Jan-Dec;14(1):2040350.

2021

Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevalleyre C, Wang CI, Evans MJ, Lebon V, Maillere B, Truillet C. Optimizing immunoPET imaging of tumor PD-L1 expression: pharmacokinetics, biodistribution and dosimetric comparisons of 89Zr-labeled anti-PD-L1 antibody formats. *J Nucl Med*. 2021 Dec 21:jnumed.121.262967.

Wang B, Goh YS, Prince T, Ngoh EZX, Salleh SNM, Hor PX, Loh CY, Fong SW, Hartley C, Tan SY, Young BE, Leo YS, Lye DC, Maurer-Stroh S, Ng LFP, Hiscox JA, Renia L, Wang CI. Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. *NPJ Vaccines*. 2021 Oct 25;6(1):125.

Wang B, Goh YS, Fong SW, Young BE, Ngoh EZX, Chavatte JM, Salleh SNM, Yeo NK, Amrun SN, Hor PX, Loh CY, Lee CY, Chan YH, Chang ZW, Tay MZ, Rouers A, Torres-Ruesta A, Carissimo G, Soh MK, Lee RTC, Xu Y, Pada S, Lin RTP, Leo YS, Lye DC, Maurer-Stroh S, Ng LFP, Renia L, Wang CI. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. *Lancet Reg Health West Pac*. 2021 Oct;15:100276.

Lee WS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, Yeo SP, Soh MK, Chan EHL, Tan LK, Tan SY, Chuah C, Chng WJ, Connolly JE, Wang CI. Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. *Mol Cancer Ther*. 2021 Jun 22:molcanther.0155.2020.

Chan YH, Fong SW, Poh CM, Carissimo G, Yeo NK, Amrun SN, Goh YS, Lim J, Xu W, Chee RS, Torres-Ruesta A, Lee CY, Tay MZ, Chang ZW, Lee WH, Wang B, Tan SY, Kalimuddin S, Young BE, Leo YS, Wang CI, Lee B, Röttschke O, Lye DC, Renia L, Ng LFP. Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. *EMBO Mol Med*. 2021 May 7:e14045.

Asarnow D, Wang B, Lee WH, Hu Y, Huang CW, Faust B, Ng PML, Ngoh EZX, Bohn M, Bulkley D, Pizzorno A, Ary B, Tan HC, Lee CY, Minhat RA, Terrier O, Soh MK, Teo FJ, Yeap YYC, Seah SGK, Chan CEZ, Connolly E, Young NJ, Maurer-Stroh S, Renia L, Hanson BJ, Rosa-Calatrava M, Manglik A, Cheng Y, Craik CS, Wang CI. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. *Cell*. 2021 Apr 24:S0092-8674(21)00536-5.

Lee CY, Amrun SN, Chee RS, Goh YS, Mak TM, Octavia S, Yeo NK, Chang ZW, Tay MZ, Torres-Ruesta A, Carissimo G, Poh CM, Fong SW, Bei W, Lee S, Young BE, Tan SY, Leo YS, Lye DC, Lin RT, Maurer-Stroh S, Lee B, Wang CI, Renia L, Ng LF. Human neutralising antibodies elicited by SARS-CoV-2 non-D614G

variants offer cross-protection against the SARS-CoV-2 D614G variant. *Clin Transl Immunology*. 2021 Feb 22;10(2):e1241.

Goh YS, Chavatte JM, Lim Jieling A, Lee B, Hor PX, Amrun SN, Lee CY, Chee RS, Wang B, Lee CY, Ngoh EZX, Wang CI, Young BE, Tambyah PA, Kalimuddin S, Pada S, Tan SY, Sun LJ, Chen MI, Leo YS, Lye DC, Ng LFP, Lin RTP, Renia L. Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. *Cell Rep Med*. 2021 Feb 16;2(2):100193.

Li CF, Chan TC, Wang CI, Fang FM, Lin PC, Yu SC, Huang HY. RSF1 requires CEBP/β and hSNF2H to promote IL-1β-mediated angiogenesis: the clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas. *Angiogenesis*. 2021 Jan 26. [Epub ahead of print]

2020

Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. *Mol Imaging Biol*. 2020 Dec;22(6):1553-1561.

Yong KSM, Her Z, Tan SY, Tan WWS, Liu M, Lai F, Heng SM, Fan Y, Chang KTE, Wang CI, Chan JKY, Chen J, Chen Q. Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics. *Front Immunol*. 2020 Oct 15;11:553362.

Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY, Chee RS, Fong SW, Yeo NK, Lee WH, Torres-Ruesta A, Leo YS, Chen MI, Tan SY, Chai LYA, Kalimuddin S, Kheng SSG, Thien SY, Young BE, Lye DC, Hanson BJ, Wang CI, Renia L, Ng LFP. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. *Nat Commun*. 2020 Jun 1;11(1):2806.

2019

Low L, Goh A, Koh J, Lim S, Wang CI. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. *Nat Commun*. 2019 Nov 26;10(1):5382.

Rajendran S, Li Y, Ngoh E, Wong HY, Cheng MS, Wang CI, Schwarz H. Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells. *Front Oncol*. 2019 Sep 24;9:945.

Ng PML, Kaliaperumal N, Lee CY, Chin WJ, Tan HC, Au VB, Goh AX, Tan QW, Yeo DSG, Connolly JE, Wang CI. Enhancing Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells by Recruiting the Intracellular Fc Receptor TRIM21. *J Immunol*. 2019 Apr 15;202(8):2307-2319.

2018

Moroz A, Lee CY, Wang YH, Hsiao JC, Sevilano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. A Preclinical Assessment of ⁸⁹Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹Zr-C4. *Bioconjug Chem*. 2018 Oct 17;29(10):3476-3482.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov

V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. *Cell*. 2018 Aug 9;174(4):938-952.e13.

Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ. Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. *Protein Eng Des Sel*. 2018 Jul 1;31(7-8):301-312.

Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jegu B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. Imaging PD-L1 Expression with ImmunoPET. *Bioconjug Chem*. 2018 Jan 17;29(1):96-103.

2017

Kam YW, Lee CY, Teo TH, Howland SW, Amrun SN, Lum FM, See P, Kng NQ, Huber RG, Xu MH, Tan HL, Choo A, Maurer-Stroh S, Ginhoux F, Fink K, Wang CI, Ng LFP, Rénia L. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. *JCI Insight*. 2017 Apr 20;2(8).

Jia Q, Ng Q, Chin W, Meng T, Chow VTK, Wang CI, Kwang J, He F. Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity. *Sci Rep*. 2017 Apr 19;7:46402.

Na Z, Yeo SP, Bharath SR, Bowler MW, Balıkcı E, Wang CI, Song H. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. *Cell Res*. 2017 Jan;27(1):147-150.

Xu M, Zuest R, Velumani S, Tukijan F, Toh YX, Appanna R, Tan EY, Cerny D, MacAry P, Wang CI, Fink K. A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. *NPJ Vaccines*. 2017 Jan 23;2:2.

2016

Xu M, Züst R, Toh YX, Pfaff JM, Kahle KM, Davidson E, Doranz BJ, Velumani S, Tukijan F, Wang CI, Fink K. Protective capacity of the human anamnestic antibody response during acute dengue infection. *J Virol*. 2016 Nov 28;90(24):11122-11131.

Chong SZ, Evrard M, Devi S, Chen J, Lim JY, See P, Zhang Y, Adrover JM, Lee B, Tan L, Li JL, Liong KH, Phua C, Balachander A, Boey A, Liebl D, Tan SM, Chan JK, Balabanian K, Harris JE, Bianchini M, Weber C, Duchene J, Lum J, Poidinger M, Chen Q, Rénia L, Wang CI, Larbi A, Randolph GJ, Weninger W, Looney MR, Krummel MF, Biswas SK, Ginhoux F, Hidalgo A, Bachelier F, Ng LG. CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses. *J Exp Med*. 2016 Oct 17;213(11):2293-2314.

Appanna R, Kg S, Xu MH, Toh YX, Velumani S, Carbajo D, Lee CY, Zuest R, Balakrishnan T, Xu W, Lee B, Poidinger M, Zolezzi F, Leo YS, Thein TL, Wang CI, Fink K. Plasmablasts During Acute Dengue Infection Represent a Small Subset of a Broader Virus-specific Memory B Cell Pool. *EBioMedicine*. 2016 Oct;12:178-188.

Eng HY, Wang CI, Xue Y, Lee CY, Binte Zulkifli S, Chiam PC, Ghadessy FJ, Lane DP. Enhanced antigen detection in immunohistochemical staining using a 'digitized' chimeric antibody. *Protein Eng Des Sel*. 2016 Jan;29(1):11-21.

2015

Porta J, Prasad VM, Wang CI, Akahata W, Ng LF, Rossmann MG. Structural Studies of Chikungunya Virus-like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. *J Virol*. 2015 Nov 4;90(3):1169-77.

2014

Goh AX, Bertin-Maghit S, Ping Yeo S, Ho A, Derks H, Mortellaro A, Wang CI. A novel human anti-interleukin-1 β neutralizing monoclonal antibody showing in vivo efficacy. *MAbs*. 2014 May 1;6(3):764-72.

2013

Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L. Use of human monoclonal antibodies to treat chikungunya virus infection. *J Infect Dis*. 2013 Jan;207(2):319-22.

2012

Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, Ong SH, Warter L, Leo YS, Wang CI, Fink K. Plasmablasts Generated during Repeated Dengue Infection Are Virus Glycoprotein-Specific and Bind to Multiple Virus Serotypes. *J Immunol*. 2012 Nov 14. [Epub ahead of print]

Irene D, Chung TY, Chen BJ, Liu TH, Li FY, Tzen JT, Wang CI, Chyan CL. Solution Structure of a Phytocystatin from *Ananas comosus* and Its Molecular Interaction with Papain. *PLoS One*. 2012; 7(11):e47865.

2011

Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, Renia L, Wang CI, Ng LF, Warter L. Chikungunya Virus Neutralization Antigens and Direct Cell-to-Cell Transmission Are Revealed by Human Antibody-Escape Mutants. *PLoS Pathog*. 2011 Dec;7(12):e1002390.

Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, Bertin-Maghit S, Ng LF, Abastado JP, Desprès P, Wang CI, Nardin A. Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency. *J Immunol*. Mar 1 2011; 186(5):3258-3264.

1998

Yang Q, Wang CI, Gillmor S, Fletteric RJ, Craik CS. Ecotin: A serine protease inhibitor with two distinct and interacting binding sites. *J Mol Biol*. 1998 Jun 19; 279(4):945-57.

1996

Wang CI, Yang Q, Craik CS. Phage display of proteases and macromolecular inhibitors. *Methods in Enzymology*. 1996; 267:52-68.

Wang CI, Yang Q, Craik CS. Altering the function of enzymes and macromolecular by phage display. Combinatorial Library: Synthesis, Screening and Application Potential. *Water De Gruyter & Co, Berlin*. 1996; 206-11.

1995

Wang CI, Yang Q, Craik CS. Isolation of a high affinity inhibitor of urokinase-type plasminogen activator by phage display of ecotin. *J. Biol. Chem.* 1995 May 19;270(20): 12250-6.

1993

Wang CI and Taylor JS. The trans-syn-1 thymine dimer bends DNA by 210° and unwinds DNA by 150°. *Chem. Res. in Toxicology*. 1993 Jul-Aug;6(4):519-23.

1992

Nadji S, Wang CI, Taylor JS. Photochemically and photoenzymatically cleavable DNA. *J Am Chem Soc.* 1992;114(24):9266-9.

Wang CI and Taylor JS. In vitro evidence that UV-induced frameshift and substitution mutations at T-Tracts are the result of misalignment-mediated replication past a specific thymine dimer. *Biochemistry*. 1992 Apr 14;31(14):3671-81.

1991

Wang CI and Taylor JS. Site-specific effect of thymine dimer formation on A-Tract bending and its biological implications. *Proc Natl Acad Sci USA*. 1991 Oct 15;88(20):9072-6.